Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	e2507821122
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	122
Issue number	21
DOIs	https://doi.org/10.1073/pnas.2507821122
State	Published - 27 May 2025

Access to Document

@article{b7e93c65eb59416da1d8367b68285fe5,

title = "Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy",

author = "Ofer Mandelboim and Angel Porgador",

year = "2025",

month = may,

day = "27",

doi = "10.1073/pnas.2507821122",

language = "אנגלית",

volume = "122",

pages = "e2507821122",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "21",

}

TY - JOUR

T1 - Engineered chemokines, resistant to cancer-mediated post-transcriptional modifications, as drugs to improve cancer immunotherapy

AU - Mandelboim, Ofer

AU - Porgador, Angel

PY - 2025/5/27

Y1 - 2025/5/27

UR - http://www.scopus.com/inward/record.url?scp=105005897690&partnerID=8YFLogxK

U2 - 10.1073/pnas.2507821122

DO - 10.1073/pnas.2507821122

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 40388627

AN - SCOPUS:105005897690

SN - 0027-8424

VL - 122

SP - e2507821122

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 21

ER -